Biohaven’s BHV-7000 program must pause new enrollment after the FDA imposed a partial clinical hold tied to a metabolite, while more than 1,200 participants have been dosed. Dosing can continue for randomized patients, and the fully enrolled BHV7000-303 study remains on track for a topline readout in the second half of 2026.

Key Highlights

  • BHV7000-303 is evaluating a 75 mg dose of BHV-7000 in refractory focal epilepsy.
  • BHV7000-302 and the associated open-label extension study continue dosing under the updated plan.
  • Biohaven paused new enrollment in its BHV-7000 program after the FDA imposed a partial clinical hold tied to a metabolite observed during rodent testing.
  • More than 1,200 participants have received BHV-7000, and dosing may continue for patients already randomized.

Biohaven Ltd. (NYSE: BHVN) is pausing new enrollment in its BHV-7000 program after the FDA imposed a partial clinical hold tied to a metabolite observed during rodent testing. More than 1,200 participants have received BHV-7000 across development, and dosing can continue for patients already randomized.

BHV-7000 Enrollment Pause Leaves Lead Study on Track

The FDA’s September 4, 2026, letter applies only to new patient enrollment while additional nonclinical studies are completed. BHV7000-302 also continues dosing, but new enrollment remains paused. The associated open-label extension study continues dosing as well.

Metabolite Review and Kv7 License Shape Next Steps

The significance of the metabolite findings for humans remains uncertain, and Biohaven said the findings may be specific to rodents. The company voluntarily extended the enrollment pause plan to its global sites outside the U.S. while dosing of already randomized patients continues across the program. The license becomes effective upon closing, and both parties continue work on the required HSR submission.